SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Oppenheimer Raises Ligand Pharmaceuticals Price Target to $346 From $334

Oppenheimer kept its Outperform rating on Ligand Pharmaceuticals.

LGND

Related stories